Moderna — co-developer (with Merck) of mRNA-4157/V940, the most advanced personalized mRNA neoantigen vaccine in the clinic.
Merck (MSD) and Moderna are advancing individualized neoantigen therapies, leveraging next-gen sequencing and deterministic algorithms to target unique tumor mutations. This sponsored content underscores the industry shift toward precision medicine that accounts for the genomic randomness driving distinct patient responses to cancer treatments.
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st
The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine simplywall.st
Moderna’s KEYNOTE-942 trial is actively assessing the efficacy of mRNA-4157 combined with pembrolizumab as adjuvant therapy for high-risk melanoma. The study compares recurrence-free survival against pembrolizumab alone in participants who have undergone complete resection.
[ACTIVE_NOT_RECRUITING · PHASE3 · Merck Sharp & Dohme LLC] The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents…
Merck Sharp & Dohme has terminated the Phase 2/3 V940-007 trial evaluating intismeran autogene (V940) plus pembrolizumab in locally resectable advanced cutaneous squamous cell carcinoma. The termination halts the development of this personalized neoantigen therapy in this specific indication, though the parallel Phase 3 melanoma study (NCT05933577) remains active and not yet recruiting.
Moderna and Merck have released five-year follow-up data for their personalized cancer vaccine candidate combined with KEYTRUDA in melanoma, demonstrating durable clinical benefit. This long-term efficacy signal is critical for validating the neoantigen vaccine platform's ability to sustain immune responses and improve survival outcomes in advanced disease.
Moderna’s individualized neoantigen therapy demonstrated broad efficacy in cancer treatment at ASCO2024. As a leading platform player, Moderna’s positive data reinforces investor confidence in the scalability and clinical utility of mRNA-based personalized vaccines across diverse tumor types.